Ayala Pharmaceuticals (ADXS) Competitors $0.03 0.00 (0.00%) (As of 12/20/2024 03:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends ADXS vs. LIXT, ADTX, FRTX, CELZ, OGEN, APM, SNPX, HEPA, INM, and PTIXShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Lixte Biotechnology (LIXT), Aditxt (ADTX), Fresh Tracks Therapeutics (FRTX), Creative Medical Technology (CELZ), Oragenics (OGEN), Aptorum Group (APM), Synaptogenix (SNPX), Hepion Pharmaceuticals (HEPA), InMed Pharmaceuticals (INM), and Protagenic Therapeutics (PTIX). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Lixte Biotechnology Aditxt Fresh Tracks Therapeutics Creative Medical Technology Oragenics Aptorum Group Synaptogenix Hepion Pharmaceuticals InMed Pharmaceuticals Protagenic Therapeutics Ayala Pharmaceuticals (NASDAQ:ADXS) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk. Is ADXS or LIXT more profitable? Ayala Pharmaceuticals' return on equity of 0.00% beat Lixte Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A Lixte Biotechnology N/A -5,562.77%-130.48% Do insiders & institutionals hold more shares of ADXS or LIXT? 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 14.8% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, ADXS or LIXT? Ayala Pharmaceuticals has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Does the MarketBeat Community prefer ADXS or LIXT? Ayala Pharmaceuticals and Lixte Biotechnology both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformAyala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes66100.00% Lixte BiotechnologyN/AN/A Which has stronger earnings and valuation, ADXS or LIXT? Lixte Biotechnology has lower revenue, but higher earnings than Ayala Pharmaceuticals. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$3.24M0.36-$48.07M-$7.980.00Lixte BiotechnologyN/AN/A-$5.09M-$1.73-1.14 Does the media prefer ADXS or LIXT? In the previous week, Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Lixte Biotechnology'saverage media sentiment score. Company Overall Sentiment Ayala Pharmaceuticals Neutral Lixte Biotechnology Neutral SummaryAyala Pharmaceuticals beats Lixte Biotechnology on 6 of the 9 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio0.0010.4289.5817.17Price / Sales0.36195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-0.015.094.774.78Net Income-$48.07M$151.83M$120.15M$225.60M7 Day PerformanceN/A-2.13%-1.92%-1.23%1 Month PerformanceN/A-3.10%11.47%3.36%1 Year PerformanceN/A11.54%30.54%16.60% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03flatN/A-95.8%$1.15M$3.24M0.0020Analyst ForecastLIXTLixte BiotechnologyN/A$2.01+1.3%N/A-5.7%$4.52MN/A-1.153Positive NewsGap UpADTXAditxt0.6193 of 5 stars$0.32-9.5%N/A-99.9%$4.48M$640,000.000.0047FRTXFresh Tracks TherapeuticsN/A$0.75flatN/A-7.5%$4.48M$10.06M-0.5320CELZCreative Medical Technology0.5873 of 5 stars$2.34+6.8%N/A-55.6%$4.10M$10,000.00-0.615Positive NewsOGENOragenicsN/A$0.33+0.2%N/AN/A$4.04M$40,000.000.005News CoverageAPMAptorum Group0.3993 of 5 stars$0.76-1.2%N/A-63.2%$3.93M$431,378.000.0030News CoverageGap DownSNPXSynaptogenix1.3995 of 5 stars$2.80+4.1%$14.00+400.0%-52.8%$3.81MN/A0.004News CoverageHEPAHepion PharmaceuticalsN/A$0.54-7.9%N/A-83.3%$3.78MN/A-0.1320INMInMed Pharmaceuticals0.437 of 5 stars$5.20-1.1%N/A-39.6%$3.73M$4.96M-0.3813News CoveragePositive NewsGap DownPTIXProtagenic Therapeutics0.8422 of 5 stars$0.54+9.1%N/A-28.0%$3.67MN/A-0.391Positive NewsGap Up Related Companies and Tools Related Companies Lixte Biotechnology Alternatives Aditxt Alternatives Fresh Tracks Therapeutics Alternatives Creative Medical Technology Alternatives Oragenics Alternatives Aptorum Group Alternatives Synaptogenix Alternatives Hepion Pharmaceuticals Alternatives InMed Pharmaceuticals Alternatives Protagenic Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADXS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
